FDA Approves ENSPRYNG — Genentech, Inc.

# FDA Approves Genentech's ENSPRYNG for Neuromyelitis Optica Spectrum Disorder The FDA has approved Genentech's ENSPRYNG (satralizumab), a subcutaneous monoclonal antibody therapy, marking a significant market entry in the rare neuroimmunological disease space and potentially positioning Genentech to capture share in the underserved neuromyelitis optica spectrum disorder market. The approval expands Genentech's immunology portfolio and addresses a treatment gap for patients with this serious neurological condition, offering investors exposure